News

JULY 1st, 2020

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

June 11, 2020

Biophytis Receives MHRA Approval to Initiate the COVA Clinical Trial in the UK with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. Read the Press Release

MAY 20, 2020

Biophytis Receives Approval from the Belgian Regulatory Agency (FAMHP) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure. Read the Press Release

APRIL 21, 2020

Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders.  Read the Press Release

April 7, 2020

Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders. Read the Press Release

March 30, 2020

Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD. Read the Press Release

March 3, 2020

Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France. Read the Press Release